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Abstract
Background: The use of human embryonic stem cells (hESCs) in research is increasing and hESCs hold the
promise for many biological, clinical and toxicological studies. Human ESCs are expected to be chromosomally
stable since karyotypic changes represent a pitfall for potential future applications. Recently, several studies have
analysed the genomic stability of several hESC lines maintained after prolonged in vitro culture but controversial
data has been reported. Here, we prompted to compare the chromosomal stability of three hESC lines
maintained in the same laboratory using identical culture conditions and passaging methods.
Results: Molecular cytogenetic analyses performed in three different hESC lines maintained in parallel in identical
culture conditions revealed significant differences among them in regard to their chromosomal integrity. In
feeders, the HS181, SHEF-1 and SHEF-3 hESC lines were chromosomally stable up to 185 passages using either
mechanical or enzymatic dissection methods. Despite the three hESC lines were maintained under identical
conditions, each hESC line behaved differently upon being transferred to a feeder-free culture system. The two
younger hESC lines, HS181 (71 passages) and SHEF-3 (51 passages) became chromosomally unstable shortly after
being cultured in feeder-free conditions. The HS181 line gained a chromosome 12 by passage 17 and a marker by
passage 21, characterized as a gain of chromosome 20 by SKY. Importantly, the mosaicism for trisomy 12 gradually
increased up to 89% by passage 30, suggesting that this karyotypic abnormality provides a selective advantage.
Similarly, the SHEF-3 line also acquired a trisomy of chromosome 14 as early as passage 10. However, this
karyotypic aberration did not confer selective advantage to the genetically abnormal cells within the bulk culture
and the level of mosaicism for the trisomy 14 remained overtime between 15%–36%. Strikingly, however, a much
older hESC line, SHEF-1, which was maintained for 185 passages in feeders did not undergo any numerical or
structural chromosomal change after 30 passages in feeder-free culture and over 215 passages in total.
Conclusion: These results support the concept that feeder-free conditions may partially contribute to hESC
chromosomal changes but also confirm the hypothesis that regardless of the culture conditions, culture duration
or splitting methods, some hESC lines are inherently more prone than others to karyotypic instability.
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Background
Human embryonic stem cells (hESCs) hold the promise
not only in cell replacement therapies but also in basic
research in a variety of fields ranging from developmental
biology, drug screening and toxicology, nutritional repro-
gramming and disease modelling [1,2]. Human ESCs are
derived from the inner cell mass of surplus embryos [1,2].
Once established, hESC lines are desired to be chromo-
somally stable. The existence of chromosomal abnormal-
ities in hESCs is an important concern, given that
karyotypic changes are often associated with carcinogene-
sis and impaired in vitro and in vivo cellular behaviour,
compromising hESC-based downstream applications.
Thus, for the potential of hESC-based therapy to be real-
ized, it is essential that these valuable cells be proven safe
and stable.
Over the last 3–4 years controversial data has been
reported regarding the chromosomal integrity of hESCs
maintained after prolonged in vitro culture [3-11]. Some
laboratories [3-8] independently showed chromosome
changes in H1, H7, H14, HS181, HS237, SA002.5, hESC5
and BG01 hESC lines; the changes emerged in most cases
beyond passage 13. In contrast, other studies [4,9-11]
reported a lack of karyotypic changes in a variety of hESC
lines (SA001, hES1-6, BG02, BG03, SA003, SA121,
SA461, HS235) grown between 34 and 140 passages. This
cytogenetic resilience of some hESC lines [4,9-11] clearly
differs from previous studies [3-8]. These controversial
findings are believed to stem from particular aspects of
cell culture methods: i) passage methods; ii) presence ver-
sus absence of feeders and iii) duration of the long-term
culture.
Regarding the passage method, it has been hypothesized
that mechanical passage of hESCs by cutting the colonies
into small pieces may contribute to the perpetuation of
the euploid population, reducing the appearance of aneu-
ploid clones which seem more common upon enzymatic
or chemical passage methodology [9,10]. The mecha-
nism/rationale behind the idea that mechanical cutting of
the hESC colonies with subsequent destruction of many
single cells within the colony is less stressful and detri-
mental for the hESC culture than enzymatic-based pas-
sage methods widely used with multiple stable primary
stem cell subsets including hematopoietic stem cells, mes-
enchymal stem cells or neural progenitors among others,
still needs to be proven and elucidated. Similarly, the cul-
ture adaptation of hESCs maintained over a feeder layer
upon being transferred to a feeder-free culture system has
been proposed as an alternative variable which may, to
some extent, favour the appearance of chromosomal
changes. As for the duration of the long-term culture, it
has also been proposed that older (that is, later passage)
cells are more susceptible to karyotypic changes than ear-
lier passage cultures. The question of how many passages
hESCs may be expanded without undergoing chromo-
somal abnormalities seems, however, somewhat aca-
demic; in some hESC lines (i.e hESC5) karyotypic insults
have been shown to occur at relatively very early passages.
Therefore, the relevance and actual biological effects of
different culture conditions and the duration of the cul-
ture on the chromosomal stability of hESCs still remains
to be elucidated.
It must be taken into account that in vitro culture of hESCs
is an abnormal condition. In vivo, the cells of the late inner
cell mass to which hESCs correspond to, do not persist but
disappear as embryogenesis progresses. Importantly,
hESCs are derived from the inner cell mass of surplus
embryos which commonly harbour chromosomal abnor-
malities [12-14]. Recent studies [13,14] reported high
rates (about 50%) of aneuploidy observed in human blas-
tocysts originating from preimplantation surplus
embryos. Among these abnormal human embryos, most
are mosaic (mixture of diploid and aneuploid cells). Blas-
tocysts donated for establishment of hESC lines are com-
monly derived either from fresh preimplantation embryos
of suboptimal quality which are not used for in utero
transfer or, more commonly from frozen embryos.
We hypothesize that, the existence of over 50% of aneu-
ploid human blastocysts, along with the emergence of
karyotypic changes in only about 20% of the hESC lines
available and grown in a number of different experienced
laboratories suggests that some hESC lines may be more
prone to karyotypic instability than others.
In the present study, we have prospectively compared
using molecular cytogenetic tools the chromosomal integ-
rity of three hESC lines, HS181, SHEF-1 and SHEF-3,
maintained in the same laboratory using identical culture
conditions and passage methods. Although feeder-free
culture conditions may partially contribute to hESC chro-
mosomal changes, we provide evidence supporting the
proof-of-principle that regardless of the culture condi-
tions, culture duration or passage methods, some hESCs
are inherently more vulnerable than others to karyotypic
instability.
Results
In the present study, we show by means of molecular
cytogenetics (G-Banding, Spectral Karyotyping [SKY] and
Comparative Genomic Hybridization [CGH]) that both,
HS181 and SHEF-3 hESC lines [5,6,15] maintained over a
layer of irradiated human foreskin fibroblasts (HFFs)
feeder cells and split using mechanical methods proved to
be karyotypically stable upon 71 and 51 passages, respec-
tively (Figure 1 &2 and Additional File 1). Both hESC lines
were euploid and neither structural chromosome changesMolecular Cancer 2008, 7:76 http://www.molecular-cancer.com/content/7/1/76
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Molecular cytogenetic analysis of HS181 hESC line Figure 1
Molecular cytogenetic analysis of HS181 hESC line. HS181 hESC line was genetically stable for 71 passages in feeders. 
Upon being transferred to feeder-free conditions and split using enzymatic methods, the HS181 hESC line gained a chromo-
some 12 as early as passage 17 and an additional marker, shown by SKY to be an extra chromosome 20 by passage 21. The 
level of mosaicism gradually increased from 26% (p17) to 89% (p30). In conventional karyotyping analysis (A) and CGH (C), the 
blue arrows indicate chromosomal gains. In the SKY images (B), the white arrows confirm the gain of chromosome 12 and 
characterized the marker seen by G-banding as a partial gain of chromosome 20.Molecular Cancer 2008, 7:76 http://www.molecular-cancer.com/content/7/1/76
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Molecular cytogenetic analysis of SHEF-3 hESC line Figure 2
Molecular cytogenetic analysis of SHEF-3 hESC line. SHEF-3 hESC line was genetically stable for 51 passages in feeders. 
Upon being transferred to feeder-free conditions and passaged using enzymatic methods, it quickly gained a trisomy of chro-
mosome 14 as early as in p10. Opposite to the HS181 line, the degree of mosaicism for the extra chromosome 14 did not 
increase overtime in feeder-free conditions and remained between 23%–36% over the culture (see Table 1). In conventional 
karyotyping analysis (A), the blue arrows indicate chromosomal gains. B,C: SKY and CGH analyses showing the absence of fur-
ther structural or numerical abnormalities.Molecular Cancer 2008, 7:76 http://www.molecular-cancer.com/content/7/1/76
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nor gains/losses of DNA content were observed (Figure 1
&2 and Additional File 1). These cells were then trans-
ferred to a feeder-free culture (matrigel-coated surface and
HFF-conditioned media [HFF-CM]) and were enzymati-
cally split by using Collagenase IV. The chromosome
integrity was determined at different culture time points
(p10, p17, p21 and p30). In a feeder-free culture system,
the HS181 cells were cytogenetically normal up to p10.
Afterwards, they gained an extra chromosome 12 as early
as p17 in 26% of the cells comprising the culture. By p21
a marker was detected by conventional karyotyping, char-
acterized as a partial gain of chromosome 20 by SKY (Fig-
ure 1 & Additional File 1). Moreover, the trisomy 12 was
found in 31% of the cells by p21. The mosaicism for tri-
somy 12 gradually increased and by p30, 89% of the cells
within the HS181 hESC culture were 47XX + 12, although
the extra chromosome 20 eventually disappeared (Figure
1 and Additional File 1). The chromosomal abnormalities
seem to be in line with the ones previously reported in
other hESC lines, affecting chromosomes 12 and, at a
lesser extent chromosome 20. The cytogenetic analysis
carried out at different culture passages (p10, p17, p21
and p30) provided evidence that key genes in specific
chromosomes (i.e. chromosome 12) may promote stem
cell self-renewal at the expense of differentiation, provid-
ing a selective proliferative/survival advantage as it is
shown by the outgrowth of the karyotypically abnormal
HS181 hESCs over their karyotypically stable counter-
parts, eventually taking over the hESC culture. In contrast,
other karyotypic changes in distinct chromosomes (i.e. an
extra chromosome 20 observed in HS181 hESCs) may
result in a delayed cell cycle and hence a slower prolifera-
tion rate, with those abnormal cells within the hESC cul-
tures eventually disappearing. Similarly, the SHEF-3 line
also acquired a trisomy of chromosome 14 as early as pas-
sage 10. However, this karyotypic aberration does not
seem to confer selective advantage to the genetically
abnormal cells within the bulk culture and the level of
mosaicism for the trisomy 14 remained over time
between 15%–36%. Importantly, these chromosomally
unstable hESC lines retained the canonical undifferenti-
ated hESC phenotype (SSEA3+, SSEA4+, Tra-1-60+, Tra-1-
81+, Oct3/4+, Nanog+, Rex-1+, Sox-2+), and the ability to
differentiate into tissues representing the three germ layers
in vivo by teratoma formation (data not shown).
Despite the fact that these data may throw more light on
the genetic stability of hESCs and its relation to how cells
are maintained in culture, caution is required when argu-
ing that culture conditions/duration may promote chro-
mosomal aberrations. For instance, Inzunza et al [8],
Buzzard et al [9] and Caisander et al [11] showed karyo-
typic changes in 4 out of 13 hESC lines maintained on
mouse or human feeders by mechanical dissociation.
Moreover, Draper et al [3] reported karyotypic changes in
hESCs maintained with or without MEFs and split either
mechanically or enzimatically [3]. Imreh et al [5] also
reported the gain of trisomy 12 in HS181 hESC line main-
tained in HFFs but passaged using enzymatic methods.
Interestingly, we show that in contrast to the HS181 and
SHEF-3 hESC lines, a much older hESC line, SHEF-1,
which had been maintained for 185 passages in feeders
(130 passages in MEFs and 55 passages in HFFs) displayed
no karyotypic changes as determined by G-banding, SKY
and CGH even after 30 passages in feeder-free conditions
despite being split by means of enzymatic methods
throughout a total of 215 passages (almost during 4 years)
(Figure 3 and Additional File 1). This data indicates that
although culture conditions might partially contribute to
chromosomal instability, some hESC lines are inherently
more predisposed than others to karyotypic changes,
being susceptible to karyotypic abnormalities regardless
the presence/absence of feeders, splitting techniques and
the duration of the culture. Therefore, this suggests that
some hESCs are inherently more prone than others to
genomic instability.
Discussion
Human ESCs have been hailed as a unique tool for bio-
medical applications such as cell replacement therapy,
developmental biology, drug discovery and disease mod-
eling [2,20]. They have the potential to become a power-
ful tool for modeling different aspects of cancer biology
that cannot otherwise be addressed by patient sample
analyses or animal models [2,20]. Many hESC down-
stream applications, however, warrant their culture under
feeder-free conditions while retaining pluripotency and
genomic integrity; otherwise, cooperating mutations
already present could prime hESCs susceptible to cellular
transformation [2,20]. Our observations of chromosomal
changes occurring only in specific hESC lines not only
suggest caution when designing novel culture conditions,
and especially feeder-free conditions but should encour-
age hESC researchers to perform regular high-resolution
molecular and cytogenetic studies to verify the chromo-
some integrity in hESCs using not only G-banding but
also CGH, SKY and more precise techniques such as SNP
assays to be able to detect tiny but biologically relevant
single nucleotide polymorphisms.
Over the last years controversial data has been reported
regarding the chromosomal integrity of hESCs main-
tained after prolonged in vitro culture [3-11]. Some labo-
ratories [3-8] independently showed chromosome
changes in several hESC lines whereas other studies [4,9-
11] reported a lack of karyotypic changes in a variety of
hESC lines. These controversial findings are believed to
stem from particular aspects of cell culture methods: i)
mechanical versus enzymatic passage methods; ii) pres-
ence versus absence of feeders and iii) duration of theMolecular Cancer 2008, 7:76 http://www.molecular-cancer.com/content/7/1/76
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Molecular cytogenetic analysis of SHEF-1 hESC line Figure 3
Molecular cytogenetic analysis of SHEF-1 hESC line. In contrast to HS181 and SHEF-3 hESC lines, the SHEF-1 hESC line 
was genetically stable after as many as 185 passages in feeders. Upon being transferred to feeder-free conditions, the SHEF-1 
hESC line displayed no karyotypic changes assessed by G-banding (A), SKY (B) and CGH (C) after further 30 passages in 
feeder-free conditions despite being split by means of enzymatic methods throughout over 215 passages (almost 4 years in in 
vitro culture). This data suggests that although culture conditions may partially contribute to chromosome stability, some hESC 
lines are inherently more predisposed than others to karyotypic changes.Molecular Cancer 2008, 7:76 http://www.molecular-cancer.com/content/7/1/76
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long-term culture. In the present study, we have compared
side-by-side three different hESC lines maintained in
identical culture conditions and found significant differ-
ences among them in regards to their chromosomal integ-
rity. All three hESC lines were chromosomally stable
when grown in feeders. However, despite being main-
tained under identical conditions, each hESC line
behaved differently upon being transferred to a feeder-free
culture system. The two younger hESC lines, became chro-
mosomally unstable shortly after being cultured on
feeder-free conditions whereas a much older hESC line
did not undergo any numerical or structural chromo-
somal change after >215 passages. While these results are
in line with the idea that feeder-free conditions may par-
tially contribute to hESC chromosomal changes they also
confirm the hypothesis that regardless of the culture con-
ditions, culture duration or splitting methods, some hESC
lines are inherently more prone than others to karyotypic
instability. Importantly, the fact that two relatively
"young" hESC lines became karyotypically abnormal by
passage 61–87 coupled to the genomic stability retained
by a much older (over 215 passages) hESC line is clear evi-
dence that the duration of the in vitro culture does not
seem to contribute to hESC genomic instability.
These data support the notion that chromosomal aberra-
tions seem to occur when hESCs are transferred to and
maintained in a feeder-free culture system and that this
phenomenon seems to vary among different hESC lines,
suggesting that hESC predisposition to karyotypic insta-
bility depends on differential vulnerability of distinct
hESC lines due to inherent properties rather than just a
cell culture adaptation process. Much work is still ire-
quired in order to identify the scope of the problem
underlying the karyotypic instability and to unravel the
intrinsic and/or extrinsic features which contribute to
making some hESCs more prone to chromosomal insta-
bility than others. Systematic inter-laboratory compari-
sons about to what extent inherent intrinsic properties
among multiple hESC lines, cytogenetic makeup of the
human pre-implantational embryos and hESC derivation
methods may contribute to the propensity to karyotypic
changes are required. We should bear in mind that in vitro
culture of hESCs is an abnormal condition. In vivo, the
cells of the late inner cell mass to which hESCs correspond
to, do not persist but disappear as embryogenesis
progresses. However, hESCs are derived from the inner
cell mass of surplus embryos which commonly harbour
chromosomal abnormalities [12-14]. Recent studies
[13,14] reported 50% rates of aneuploidy observed in
human blastocysts originating from preimplantation sur-
plus embryos. Among these abnormal human embryos,
most are mosaic (mixture of diploid and aneuploid cells).
Blastocysts donated for establishment of hESC lines are
commonly derived either from fresh preimplantation
embryos of suboptimal quality which are not used for in
utero transfer or, more commonly from frozen embryos.
This poses many unresolved questions about hESC in vitro
culture and genomic stability: i) Are hESCs derived from
frozen embryos more prone to genomic instability than
those derived from fresh embryos? ii) If 40%–50% of the
human IVF embryos are karyotypically abnormal, why
almost 100% of the newly derived hESC lines are euploid?
Is this because karyotypically abnormal embryos cannot
progress in vitro into a hESC line? iii) Are only the euploid
blastomeres in IVF mosaic embryos responsible for col-
ony outgrowth and hESC establishment? iv) Are hESC
lines originally derived in a feeder-free system more vul-
nerable to chromosomal changes than those derived on
feeders?
Recent elegant work indicates that cancer may arise from
tissue stem cells in adults, and that many cell-signalling
pathways essential for normal development (e.g. BMP,
Notch, Wnt and Hedgehog) are involved in cancer pro-
gression, suggesting a link between embryonic cells and
cancer cells [2,22]. The fact that cellular transformation
manifests as a blockage or altered cell differentiation sug-
gests that in vitro hESC differentiation could become a
promising tool for studying cancer biology and the emer-
gence of transformation events by characterizing the
genetic and epigenetic mechanisms that drive cell trans-
formation rather than normal cell specification. Accord-
ingly, it is worth mentioning that the derivation and/or
establishment of hESCs carrying specific chromosome
abnormalities or characterized mutations may represent
an unprecedented tool to dissecting cellular and molecu-
lar mechanisms underlying cancer biology by likely dis-
rupting the balance between self-renewal, differentiation
and cell death. In fact, our data reveal how distinct cytoge-
netic abnormalities result in different biological effect. For
instance, extra copies of key genes in specific chromo-
somes (i.e. chromosome 12) may promote hESC self-
renewal at the expense of differentiation, providing a
selective proliferative/survival advantage as shown by the
outgrowth of the karyotypically abnormal hESCs over
their karyotypically stable counterparts, eventually taking
over the hESC culture. In contrast, extra copies of genes in
other chromosomes (i.e. chromosome 14 or 20) might
result in either no effect or a delayed cell cycle and hence
a slower proliferation rate, with those abnormal cells
within the hESC cultures eventually disappearing.
Methods
Human ESC culture
The human ESC lines HS181, SHEF-1 and SHEF-3 were
maintained either in tissue-treated T25 flasks (BD Bio-
sciences, Bedford, MA) over a confluent (0.5–1 × 105
feeder cells/cm2) layer of X-ray inactivated (4000 rads)
HFFs (ATCC; SCD-1112SK) or MEFs in hESC media con-Molecular Cancer 2008, 7:76 http://www.molecular-cancer.com/content/7/1/76
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sisting of 80% KO-DMEM supplemented with 20% KO
Serum replacement, 1% nonessential amino acids, 1 mM
L-Glutamine, 0.1 mM β-mercaptoethanol and 8 ng/mL of
basic fibroblast growth factor (bFGF) (all from Invitrogen,
CA) [16] or cultured in Matrigel (BD Biosciences)-coated
T25 flasks in human foreskin fibroblast (HFF)-condi-
tioned medium (HFF-CM) supplemented with 8 ng/mL
bFGF [17]. To maintain undifferentiated growth, the
media (hESC media or HFF-CM) was changed daily, and
the cells were split (1:2) weekly by dissociation with 200
U/mL of collagenase IV (Invitrogen).
Conventional karyotyping
hESCs were cultured in medium supplemented with 0,1
mg/mL colcemid (Biological Industries) for up to 3–4
hours. The cells were then washed in Versene solution
(Gibco) and subsequently trypsinized and spun down.
The pellet was resuspended carefully in a KCL hypotonic
solution (0,075 mol/L), rinsed to remove the cytoplasm,
and then fixed in methanol/acetic acid 3:1. The fixing pro-
cedure was repeated three times. Finally, the pellet was
resuspended in a final volume of 1 mL of fixative, and the
cells were dropped onto glass slides. Chromosomes were
visualized by using a modified Wright's staining. At least
25 metaphases were analyzed for each cell line using a
conventional microscope and the IKAROS-software
(Metasystems) [18,19].
Comparative genomic hybridization
Genomic DNA from hESCs was obtained using the Qia-
gen DNA isolation kit. Human ESC DNA labeling with
fluorescent (Spectrum Green) dUTP was performed using
Nick Translation according to Vysis's protocol. Human
male gDNA labeled with Spectrum Red was used as refer-
ence. After labeling, the length of the DNA fragments were
verified by gel electrophoresis to ensure they ranged from
300–3000 bp.
Human ESC labeled-DNA and the reference labeled-DNA
were simultaneously hybridized to normal metaphase
chromosomes in the presence of Cot-1 DNA to block
repetitive sequences. After CGH hybridization in a moist
chamber for 48 h, the slides were washed once in 0,4 ×
SSC/0,3% NP-40 at 73°C for 2 minutes, followed by 2 ×
SSC/0,1% NP-40 at RT for 1 minute. The slides were air-
dried in the darkness and the chromosomes counter-
stained with DAPI. Twenty metaphases were captured and
evaluated for each cell sample [18]. Red/Green ratios
higher than 1.25 indicated deleted regions and ratios
below 0.80 indicated amplified regions. The CGH quality
control test was analyzed using a 99.5% confidence inter-
val. For data analysis, an automated fluorescence micro-
scope system (Nikon Eclipse 50i) equipped with
appropriate filters and Metasystem CGH software pro-
gram was used [8,18,19]
Spectral karyotyping
For SKY analysis, slides were hybridized using the SKY
method according to the manufacturer's protocol
(Applied Spectral Imaging, Migdal Ha'Emek, Israel).
Images were acquired with an SD300 Spectra Cube
(Applied Spectral Imaging) mounted on a Zeiss Axioplan
microscope using a custom-designed optical filter (SKY-1;
Chroma Technology, Brattleboro, VT). Twenty met-
aphases were analyzed for each sample. SKY is somewhat
limited in the determination of breakpoints and in the
identification of intrachromosomal changes such as
duplications, deletions, and inversions [8,18-21]. As a
result, breakpoints on the SKY-painted chromosomes
were determined by comparison of corresponding DAPI
banding and by comparison with G-banding karyotype of
the hESC line.
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